JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

Search

Bio-Techne Corp

Fermé

SecteurSoins de santé

64.54 -1.44

Résumé

Variation du prix de l'action

24h

Actuel

Min

63.91

Max

65.63

Chiffres clés

By Trading Economics

Revenu

-176K

38M

Ventes

9.3M

296M

P/E

Moyenne du Secteur

125.923

121.746

Rendement du dividende

0.48

Marge bénéficiaire

12.846

Employés

3,100

EBITDA

-135K

78M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+9.48% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.48%

2.26%

Prochains Résultats

6 mai 2026

Date du Prochain Dividende

27 févr. 2026

Date du Prochain Détachement de Dividende

16 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

78M

10B

Ouverture précédente

65.98

Clôture précédente

64.54

Sentiment de l'Actualité

By Acuity

41%

59%

124 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Bio-Techne Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 nov. 2025, 22:36 UTC

Résultats

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Comparaison

Variation de prix

Bio-Techne Corp prévision

Objectif de Prix

By TipRanks

9.48% hausse

Prévisions sur 12 Mois

Moyen 73.11 USD  9.48%

Haut 80 USD

Bas 65 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

7

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

49.67 / 50.24Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Strong Bearish Evidence

Sentiment

By Acuity

124 / 352Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat